Advanced Cervical Cancer Pipeline, Clinical Trials Studies, Emerging Drugs, Mergers and Acquisition, Licensing, Agreements & Collaborations, and Latest News 2023 (Updated)

 Breaking News
  • No posts were found

Advanced Cervical Cancer Pipeline, Clinical Trials Studies, Emerging Drugs, Mergers and Acquisition, Licensing, Agreements & Collaborations, and Latest News 2023 (Updated)

November 30
09:31 2023
Advanced Cervical Cancer Pipeline, Clinical Trials Studies, Emerging Drugs, Mergers and Acquisition, Licensing, Agreements & Collaborations, and Latest News 2023 (Updated)

DelveInsight’s, “Advanced Cervical Cancer Pipeline Insight 2023” report provides comprehensive insights about 70+ companies and 75+ pipeline drugs in Advanced Cervical Cancer pipeline landscape. It covers the Advanced Cervical Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Advanced Cervical Cancer pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key Takeaways from the Advanced Cervical Cancer Pipeline Report

  • DelveInsight’s Advanced Cervical Cancer pipeline report depicts a robust space with 70+ active players working to develop 75+ pipeline therapies for Advanced Cervical Cancer treatment.
  • The leading companies working the Advanced Cervical Cancer Market include AstraZeneca, GlaxoSmithKline, Advaxis, Bristol-Myers Squibb, Innovent Biologics, Shanghai Henlius Biotech, Biocad, Genexine, Inc., Merck KGaA, Zeria Pharmaceutical, ISA Pharmaceuticals, Agenus Inc., Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Vaccibody AS, Fujifilm Pharmaceuticals U.S.A., Inc., NETRIS Pharma,CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Xencor, Inc., Sotio a.s., Andes Biotechnologies, and others.
  • Promising Advanced Cervical Cancer Pipeline Therapies in the various stages of development include Durvalumab, Cisplatin, Carboplatin, IBI310, and others.
  • November 2023: NETRIS Pharma announced a study of Phase 1 & 2 clinical trials for NP137, Pembrolizumab, Paclitaxel, and Carboplatin. The aim of this study is to investigate the safety and the clinical activities of NP137 when combined with pembrolizumab and/or chemotherapies in patients with advanced/metastatic gynecological cancers (2 types: endometrial carcinoma and cervix carcinoma).
  • November 2023: Bristol-Myers Squibb announced a study of Phase 1 & 2 clinical trials for BMS-986340 and Docetaxel. The purpose of this study is to assess the safety, tolerability, and recommended dose(s) of BMS-986340 as monotherapy and in combination with nivolumab or docetaxel in participants with advanced solid tumors. This study is a first-in-human (FIH) study of BMS-986340 in participants with advanced solid tumors.
  • November 2023: Merck Sharp & Dohme LLC announced a study of Phase 2 clinical trials for pembrolizumab. In this study, participants with multiple types of advanced (unresectable and/or metastatic) solid tumors who have progressed on standard of care therapy will be treated with pembrolizumab (MK-3475).
  • November 2023: Nurix Therapeutics Inc. announced a study of Phase 1 clinical trials for NX-1607 and Paclitaxel. This is a first-in-human Phase 1a/1b multicenter, open-label oncology study designed to evaluate the safety and anti-cancer activity of NX-1607 in patients with advanced malignancies.
  • November 2023: Seagen Inc. announced a study of Phase 1 clinical trials for sasanlimab and brentuximab vedotin. The study will have four parts. Part A of the study will find out how much SEA-TGT should be given to patients. Part B will use the dose found in Part A to find out how safe SEA-TGT is and if it works to treat solid tumors and lymphomas. Part C will study how well SEA-TGT with sasanlimab works to treat solid tumors. Part D will study how well SEA-TGT with brentuximab vedotin works to treat classical Hodgkin lymphoma (cHL).
  • November 2023: AstraZeneca announced a study of Phase 3 clinical trials for Volrustomig. This is a phase III, randomized, double-blind, placebo-controlled, multi-center, global study to explore the efficacy and safety of volrustomig in women with high-risk LACC (FIGO 2018 stage IIIC to IVA cervical cancer with lymph node involvement) who have not progressed following platinum-based CCRT.

 

Request a sample and discover the recent advances in Advanced Cervical Cancer Treatment Drugs @ Advanced Cervical Cancer Pipeline Report

 

In the Advanced Cervical Cancer pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Advanced Cervical Cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

Advanced Cervical Cancer Overview

Advanced cervical cancer means the cancer has spread from the cervix to another area of the body such as the lungs. Sometimes cancer is advanced when it is first diagnosed. Unfortunately advanced cancer can’t usually be cured. But treatment might control it, help symptoms, and improve your quality of life for a while.

 

Find out more about Advanced Cervical Cancer Therapeutics Assessment @ Advanced Cervical Cancer Preclinical and Discovery Stage Products

 

Advanced Cervical Cancer Emerging Drugs Profile

  • Imfinzi (durvalumab): AstraZeneca
  • Dostarlimab: GlaxoSmithKline
  • Andes 1537: Andes Biotechnologies

 

Advanced Cervical Cancer Pipeline Therapeutics Assessment

There are approx. 70+ key companies which are developing the therapies for Advanced Cervical Cancer. The Advanced Cervical Cancer companies which have their Advanced Cervical Cancer drug candidates in the most advanced stage, i.e. phase III include, AstraZeneca.

 

DelveInsight’s Advanced Cervical Cancer pipeline report covers around 75+ products under different phases of clinical development like

  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates

 

Advanced Cervical Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Oral
  • Parenteral
  • Intravenous
  • Subcutaneous
  • Topical.

 

Advanced Cervical Cancer Pipeline Products have been categorized under various Molecule types such as-

  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy

 

Learn more about the emerging Advanced Cervical Cancer Pipeline Therapies @ Advanced Cervical Cancer Clinical Trials Assessment

 

Scope of the Advanced Cervical Cancer Pipeline Report

  • Coverage- Global
  • Advanced Cervical Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Advanced Cervical Cancer Therapeutics Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
  • Advanced Cervical Cancer Companies- AstraZeneca, GlaxoSmithKline, Advaxis, Bristol-Myers Squibb, Innovent Biologics, Shanghai Henlius Biotech, Biocad, Genexine, Inc., Merck KGaA, Zeria Pharmaceutical, ISA Pharmaceuticals, Agenus Inc., Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Vaccibody AS, Fujifilm Pharmaceuticals U.S.A., Inc., NETRIS Pharma,CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Xencor, Inc., Sotio a.s., Andes Biotechnologies, and others.
  • Advanced Cervical Cancer Pipeline Therapies- Durvalumab, Cisplatin, Carboplatin, IBI310, and others.

 

Dive deep into rich insights for new drugs for Advanced Cervical Cancer Treatment, Visit @ Advanced Cervical Cancer Market Drivers and Barriers, and Future Perspective

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. Advanced Cervical Cancer: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Advanced Cervical Cancer – DelveInsight’s Analytical Perspective
  7. In-depth Commercial Assessment
  8. Advanced Cervical Cancer Collaboration Deals
  9. Late Stage Products (Phase III)
  10. Durvalumab: AstraZeneca
  11. Drug profiles in the detailed report…..
  12. Mid Stage Products (Phase II)
  13. Dostarlimab: GlaxoSmithKline
  14. Drug profiles in the detailed report…..
  15. Early Stage Products (Phase I)
  16. Andes 1537: Andes Biotechnologies
  17. Drug profiles in the detailed report…..
  18. Inactive Products
  19. Advanced Cervical Cancer Key Companies
  20. Advanced Cervical Cancer Key Products
  21. Advanced Cervical Cancer- Unmet Needs
  22. Advanced Cervical Cancer- Market Drivers and Barriers
  23. Advanced Cervical Cancer- Future Perspectives and Conclusion
  24. Advanced Cervical Cancer Analyst Views
  25. Advanced Cervical Cancer Key Companies
  26. Appendix

 

For further information on the Advanced Cervical Cancer Pipeline therapeutics, reach out to Advanced Cervical Cancer Unmet Needs and Analyst Views

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/major-depressive-disorder-market

Related Articles

Categories